TechnoVax and its team of scientists have developed a new way to produce highly immunogenic, non-infectious monovalent and polyvalent virus-like particle (VLP) vaccines, using a cell-based manufacturing system.
Virus-like particles are structures that mimic the organization and conformation of native viruses but are non-infectious because they do not contain any viral genetic material, potentially yielding safer and cheaper vaccine candidates.
Our Unique and Novel VLPs (Virus-Like Particle) and Inhaled Powder platforms are used to develop and produce vaccines against infectious diseases such as:
- Influenza (mono or multivalent, universal flu vaccines)
- Respiratory Syncytial Virus (RSV vaccine),
- Para-Influenza (PIV) and other diseases including Dengue, HIV and cancer.